This seems like a golden age for those struggling with weight. The arrival of Ozempic, Wegovy, and other GLP-1 agonists is offering hope where there was none. It's also presenting employers across our country with a tough decision: how best to cover, or not to cover, such high-demand, high-cost drugs?

The headlines make it all sound so simple, an easy "yes, definitely," but the best counsel is actually to take a beat and zoom out. Before handing over the syringe, companies debating whether or not to cover for these medications should study the big picture first, and look at the facts as we know them.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events
  • Access to other award-winning ALM websites including and

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.